Discussing axSpA: Biologic therapy outcomes in axial spondyloarthritis

Discussing RA: Comparative outcomes with upadacitinib in RA

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review papers by Mysler et al. and Taylor et al, in which authors explore how different treatment strategies may improve outcomes in patients with RA.

EULAR 2026 Preview Podcast

Join Professor Xenofon Baraliakos as he guides you through what we are most looking forward to in RA, PsA, and axSpA at EULAR 2026, so that you can better plan your time at what will be a busy and exciting congress

Discussing axSpA: Biologic therapy outcomes in axial spondyloarthritis

Join Dr Sofia Ramiro and Professor Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered how certolizumab pegol reduces anterior uveitis flares in high-risk axSpA and the effect of secukinumab dose escalation on MRI inflammation and damage in axSpA.

Author Interview: Professor Valentino Paci, April 2026

Join Professor Peter Nash from the Griffith University in Brisbane, and am Professor Valentino Paci, Medical researcher specialized in immune-mediated diseases, with a particular focus on spondyloarthritis. Collaboration and knowledge exchange are integral to his research philosophy, as they discuss his recent paper ‘Does Prior Exposure Affect Retention? A Real‑World, Multicentre Assessment of IL‑17 Inhibitor Cycling in Psoriatic Arthritis?’.

Discussing RA: Updated EULAR recommendations and next-step strategies after TNF inhibitor failure

Join Professor Iain McInnes and Professor Rieke Alten for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, they will review a paper by Smolen et al. provides an update of the EULAR RA management recommendations addressing the most recent insights; and by Narváez et al. developed evidence-informed, profile-based recommendations to guide treatment selection after inadequate response to a first TNFi in RA, combining evidence and expert consensus.